We serve Chemical Name:1-(4-Methoxybenzyl)piperidine-2,4-dione CAS:712353-75-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(4-Methoxybenzyl)piperidine-2,4-dione
CAS.NO:712353-75-8
Synonyms:1-[(4-methoxyphenyl)methyl]piperidine-2,4-dione
Molecular Formula:C13H15NO3
Molecular Weight:233.26300
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:46.61000
Exact Mass:233.10500
LogP:1.32460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-[(4-methoxyphenyl)methyl]piperidine-2,4-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[(4-methoxyphenyl)methyl]piperidine-2,4-dione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[(4-methoxyphenyl)methyl]piperidine-2,4-dione Use and application,1-[(4-methoxyphenyl)methyl]piperidine-2,4-dione technical grade,usp/ep/jp grade.
Related News: The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. tert-Butyl-{2-[8-(4-methoxy-1,3-dimethyl-cyclohexa-2,4-dienyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-ethoxy}-diphenyl-silane manufacturers UQUIFA is a manufacturer of APIs and intermediates for the pharmaceutical industry globally. The company has 3 manufacturing sites (2 in Spain and 1 in Mexico) with strict adherence to all regulatory norms. Oxidase, cytochrome (Cercaria batillariae strain HL2 clone haplotype5gene COXI C-terminal fragment) suppliers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. (Z)-6-Ethoxy-1,2,3,4,5,6-hexaphenyl-hex-5-en-1-one vendor & factory The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.,As the Covid-19 pandemic continues to challenge the global drug supply chain, nations are looking for new ways to enable native producers to continue scaling up. Now, an Israeli API maker is dropping a down payment into an Indian intermediates company to ramp up its own manufacturing base.
